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Abstract
Background Periprocedural myocardial infarction (MI) is a fre-
quent complication of percutaneous coronary intervention (PCI).
Statins might reduce its incidence. The aims of the present
study are to assess whether such benefit is a class-effect orwheth-
er differences exist between various lipid-lowering strategies and
whether cardioprotection is exerted by increasing circulating en-
dothelial progenitor cells (EPCs).
Methods The REMEDY study will enroll a total of 1080 pa-
tients submitted to elective PCI. Eligible patients will be random-
ized into 4 groups: 1) placebo; 2) atorvastatin (80 mg + 40 mg
before PCI); 3) rosuvastatin (40 mg twice before PCI); and 4)
rosuvastatin (5 mg) and ezetimibe (10 mg) twice before PCI.
Peri-procedural MI is defined as an elevation of markers of car-
diac injury (either CK-MB or troponin I or T) values >5x the
upper reference limit estimated at the 99th percentile of the nor-
mal distribution, or a rise >20 % in case of baseline values al-
ready elevated. EPCs will be assessed before, at 24 h and - in a
subset of diabetic patients - at 3 months after PCI (EPC-
substudies). The primary endpoint of the main REMEDY study
is the rate of peri-procedural MI in each of the 4 treatment arms.
Secondary endpoints are the combined occurrence of 1-month
major adverse events (MACE, including death, MI, or the need
for unplanned revascularization); and any post-procedural in-
crease in serum creatinine. Endpoints of the EPC-substudies
are the impact of tested regimens on 1) early (24-h) and
3-month EPC levels and functional activity; 2) stent strut re-
endothelialization and neointimal hyperplasia; 3) 1-year
MACE. REMEDY will add important information on the
cardioprotective effects of statins after PCI.
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Background
Periprocedural myocardial infarction (MI) is a frequent compli-
cation of percutaneous coronary intervention (PCI), occurring in
up to 40 % of cases [1, 2]. Although most patients remain
asymptomatic and with no changes in cardiac function, even a
mild release of creatine kinase-MB isoenzyme (CK-MB) is
associated with higher mortality during the follow-up [2].
Randomized studies have demonstrated that HMG-CoA re-
ductase inhibitors (statins) might reduce the incidence of
periprocedural MI in both stable and acute settings [3–10].
At present, however, few data exist on whether this myo-
cardial protection should be considered as a class-effect and
whether one statin is superior to others [11–15]. In addition,
mechanisms responsible of this beneficial effect have not
been elucidated, although many so-called Bpleiotropic^ effects
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have been advocated. The anti-inflammatory properties of
statins may play an important role, because of the demonstra-
tion that the benefit appears to be higher in patients with high
C-reactive protein [16–24]. Statin administration also rapid-
ly improves endothelial function [25]. Indeed, even short-
term treatment with statins (unable to provide LDL
reduction persistent enough to decrease the atherosclerotic
burden) may have important effects on endothelial function
[25–27]. In the present Rosuvastatin For REduction Of
Myocardial DamagE During Coronary AngioplastY
(REMEDY) trial we will assess whether the beneficial ef-
fect of statins in reducing periprocedural MI 1) is a class-
effect or, on the contrary, differences exist between
rosuvastatin, atorvastatin and the rosuvastatin/ezetimibe
combination, and 2) is due to their effects on endothelial
progenitor cells (REMEDY-EPC studies).
Methods
Patient Population
This is a multicenter, prospective, randomized, double-blind,
double-dummy, placebo-controlled trial on all-comers with
coronary artery disease (CAD) candidate to an elective PCI,
both treated or untreated with statins. Inclusion and exclusion
criteria are reported in Table 1. Written informed consent for
participation to the study will be obtained from each enrolled
subject before randomization. The current study protocol is an
Investigator-Initiated study (ISS), proposed and endorsed by
the Italian Federation of Cardiology Gruppo di Studio
Aterosclerosi, Trombosi e Biologia Vascolare (ATBV Study
Group), partially funded by AstraZeneca and by a Programma
Operativo Nazionale (PON) Ricerca e Competitività 2007–
2013 PON01_02342, and will be performed through a net-
work of hospitals belonging to the two main Italian National
Societies, Società Italiana di Cardiologia, Associazione
Nazionale Medici Cardiologi Ospedalieri, as well as the
Gruppo Italiano Studi Emodinamici, on a voluntary basis
(Appendix 1). The trial will be conducted according to the
principles of the Declaration of Helsinki and Good Clinical
Practice, and has been approved by the Ethic Committees of
each participating center. The trial has been registered with
Europeac Clinical Trials Register (EudraCT Number: 2009–
013,622-17).
Randomization
Randomization will be performed by a central randomization,
concealed with the use of a web-based system. Randomization
sequence will be computer-generated and blocked.
Randomization will be 1:1:1:1. Outcome evaluation will be
performed on patients randomized and receiving a PCI.
Patients admitted to the study will be randomized into 4
parallel groups (Fig. 1): 1) standard background treatment
(i.e., performing PCI on the background of standard treat-
ment, without any change of the therapy received by the
patient, according to local practice) + placebo twice immedi-
ately before the PCI; 2) standard background treatment +
atorvastatin, (given 80mg + 40mg before PCI (7); 3) standard
background treatment + rosuvastatin (40 mg twice before
PCI); and 4) standard background treatment + rosuvastatin
(5 mg) and ezetimibe (10 mg) twice before PCI (dosages ex-
pected to be equipotent, in terms of LDL cholesterol reduction,
to the rosuvastatin regimen, but testing a largely HMG-
CoA reductase inhibition-independent way of reducing
LDL cholesterol). The first dosage of the tested drug will
be given within a time interval of 24–12 h before the
planned procedure. The second dosage will be given im-
mediately (within a time interval of 1 h-10 min) before the
start of the PCI. The protocol includes two substudies to
be conducted at specific sites, the REMEDY-EPC early
substudy (performed as a single-center substudy at the
University Cardiology Division, SS. Annunziata Hospital,
Chieti, Italy), enrolling consecutive patients with stable cor-
onary artery disease (CAD) (Fig. 2); and the REMEDY-
EPC late substudy (performed as a single-center substudy
Table 1 Inclusion and exclusion criteria
Inclusion criteria
Patients treated by percutaneous coronary revascularization with stent
implantation
Age ≥ 18 years
Stable angina
Stable post-acute coronary syndrome (bothwith andwithout ST-segment
elevation) with stabilised biomarkers (troponin and/or CK-MB)*
Male or female able to understand and sign a witnessed informed
consent
Exclusion criteria
Age < 18 years
Ongoing or recent (<48 h) episode of ST-elevation or non-STelevation
myocardial infarction with not stabilized biomarkers*
Any previously known increase in liver enzymes ascribed to liver
dysfunction at baseline
History of liver toxicity or myopathy on previous treatment with statins
Left ventricular ejection fraction <30 %
Renal insufficiency, with creatinine >2 mg/dL at baseline
Ongoing treatment with high-dose statins (atorvastatin 80 mg or
rosuvastatin 40 mg)
Pregnant or lactating women
Simultaneous participation in another drug or device study
Lack to obtain informed consent
*with variations <20 % in 2 consecutive measurements obtained at 6 h
distance before percutaneous intervention
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at the Clinica Mediterranea, Naples, Italy), enrolling con-
secutive patients with stable coronary artery disease (CAD)
and diabetes mellitus (Fig. 3).
Percutaneous Coronary Intervention
Stents will be implanted according to current clinical practice. In
order to limit additional confounders, all diabetic patients en-
rolled in the REMEDY-EPC late substudy will be treated by
the same drug-eluting stent (DES) type, specifically the
Cre8™ Amphilimus sirolimus eluting stent (Cre8 AES;
Alvimedica, Istanbul, Turkey) 1) to prevent confounding effects
due to differences between various DES, and 2) to follow the
promising preliminary results of this DES in diabetic patients
[28]. Cre8™ is a polymer-free sirolimus-eluting stent with a thin
(80 μm) L605 cobalt-chromium alloy, integrally coated by an
ultra-thin (0.3 μm) passive carbon coating (i-Carbofilm™).
Angiographic success is defined as a final angiographic residual
stenosis of <20 % by visual estimation. Procedural success is
considered in cases of angiographic success and the absence of
any in-hospital major complication (acute MI, need for bypass
surgery or repeat PCI, or death). Angiographic complications
include: minor/major side branch compromise or occlusions;
abrupt intra-procedural vessel closure; major arterial dissection;
thrombus formation; transient and/or prolonged slow-no reflow;
distal embolization; coronary perforation. All patients will
receive daily aspirin (100 mg/day) and a thienopyridine
[usually clopidogrel 75 mg/day if on chronic (>3 day) treat-
ment, or 600 mg loading at least 6 h before the procedure]. All
patients will receive an intravenous bolus of unfractionated
heparin (70 IU/kg) or bivalirudin (bolus of 0.75 mg/kg prior
to the start of the intervention, followed by infusion of
1.75 mg/kg/h) for the duration of the procedure, according
to the operator’s preference. Additional heparin or bivalirudin
boluses will be given to maintain an activated clotting
time > 250 s. For the REMEDY-EPC late substudy, the acti-
vated clotting time will be measured on the ACT PLUS®
Automated Coagulation Timer System (Medtronic Vascular
Inc., Santa Rosa, CA) 5 min after heparin administration.
Glycoprotein IIb/IIIa inhibitors will be administered according
to operators’ preference.
Postprocedure Management and Follow-up
Aspirin (100 mg/day), and clopidogrel (75 mg daily for
30 days in case of bare metal stents or 6–12 months in case
Fig. 1 Study design of the REMEDY trial. 1. standard background
treatment (i.e., performing PCI on the background of standard
treatment, without any change of the therapy received by the patient,
according to local practice) + placebo twice immediately before the
PCI; 2. standard background treatment + atorvastatin, given 80 mg +
40 mg before PCI; 3. standard background treatment + rosuvastatin
40 mg twice before PCI; 4. standard background treatment +
rosuvastatin 5 mg + 10 mg ezetimibe twice before PCI. Additional
determinations performed in the REMEDY-EPC late sub-study, are
detailed in Fig. 3
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of DES) will be prescribed after PCI. All patients will be
discharged on statins according to the local practice and
preference. Diabetic patients enrolled into the REMEDY-
EPC late substudy will be further randomized into 2
groups: 1) receiving standard background treatment and high
(80 mg/day) atorvastatin dose for 3 months (Atorvastatin
High-Dose Group); and 2) receiving standard background
treatment and low (20 mg/day) atorvastatin dose for 3 months
(Atorvastatin Low-Dose Group). These subgroups of patients
will be scheduled for re-hospitalization at 3 months in order to
assess 1) EPC levels, 2) glyco-metabolic control, and 3) the
degree of stent strut re-endothelialization and intrastent neoin-
tima hyperplasia evaluated by optical coherence tomography
(OCT) in the 2 treatment groups (high- versus low-dose ator-
vastatin) (Fig. 3).
Study Endpoints
The primary endpoint of the REMEDY study is the rate of
periprocedural MI in each of the 4 treatment arms.
Periprocedural MI is defined as an elevation of troponin (either
I or T) values >5 x 99th percentile upper reference limit (URL)
in patients with normal baseline values (≤99th percentile URL)
or a rise of troponin values >20 % if the baseline values
were elevated and are stable or falling [29]. Secondary
endpoints are: 1) the combined occurrence of 1-month ma-
jor adverse cardiovascular events (MACE, including death,
MI, stroke or the need for unplanned revascularization) in the
4 treatment arms. 2) any post-procedural increase in serum
creatinine or decrease in creatinine clearance (calculated by
the Cockcroft-Gault formula) in the 4 treatment arms, in order
also to assess possible beneficial effects of treatments on
contrast-induced acute kidney injury (CI-AKI).
Endpoints of the REMEDY-EPC substudies are 1) to
examine whether preprocedural exposure to different
statins can acutely (within 24 h) increase EPC levels and
functional activity (with potential differences between
treatments) compared with a standard treatment in patients
with stable CAD undergoing successful PCI; 2) to examine
whether statin-induced changes in EPC levels and function are
quantitatively related, and therefore potentially causally
linked, with the acute effects on postprocedural MI; 3) for
the REMEDY-EPC late substudy: to assess whether statin
dose (atorvastatin 80 mg/day versus 20 mg/day) induces dif-
ferent 3-month changes in EPC levels in diabetic patients
treated by DES implantation; 4) to assess whether EPC levels
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Fig. 2 Study design of the REMEDY-EPC early substudy. CAD patients
enrolled will be randomized in 4 groups according to the treatment
strategy reported in Fig. 1. Sampling for EPC levels will be performed
at the time of randomization to placebo or lipid-lowering treatments
(sample R), and 1 h before the diagnostic angiography and PCI at time
of treatment reload (placebo or lipid-lowering treatments, sample T0).
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may influence stent struts re-endothelialization and neointimal
hyperplasia, as assessed by OCT at the 3-month follow-up;
and 5) to assess the impact of EPC levels at different times
(pre-PCI, 24 h and 3-month after PCI) on the 12-month oc-
currence of MACE.
Biochemical Parameters
Blood samples will be taken twice before (possibly at admis-
sion and immediately before the PCI, in any case at least at 6 h
distance) and then at 6, and 24 h after the procedure, to assay
CK-MB (measured by mass assay) and/or cardiac troponin
(TnI or TnT), and serum creatinine. Total cholesterol, low-
density lipoprotein cholesterol (LDL-C), high-density lipo-
protein cholesterol (HDL-C), triglycerides, high-sensitivity
C-reactive protein (CRP), aspartate and alanine transaminases
(safety evaluation) will be assessed at admission. Additional
determinations, such as those in the proposed REMEDY-EPC
substudies, will be performed at the discretion of participating
investigators and are detailed separately (Appendix 2).
Sampling at 48 h will be optional, in case of abnormal
markers in previous samples. Measurements of CK-MB
mass and/or TnI or TnT will be performed locally [30].
Upper normal limits are defined as the 99th percentiles
of the normal population, with a total imprecision of
<10 %, according to the Joint European Society of
Cardiology/American College of Cardiology guidelines [31].
Serum creatinine will be measured by standard clinical chem-
istry techniques.
Clinical Follow-up
Clinical follow-up at one, 3, 6 and 12 months will be obtained
by office visit or telephone call in all patients to assess the
occurrence of MACE. An electrocardiogram and a detailed
medical history of any event occurred during the follow-up
will be obtained. Additional testing will be left to the discre-
tion of the investigators. Diabetic patients enrolled into the
REMEDY-EPC late substudy will be scheduled for a 3-
month re-hospitalization in order to assess 1) EPC levels and
2) the degree of stent struts endothelization and neointimal
hyperplasia at 3 months by OCT evaluation (Fig. 3). Details
FIRST 
RANDOMIZATION
PCI with Cre8 AES implantation
CK-MB mass and/or Tp , serum creatinine and EPC at 24 hours after PCI
Diabetic Patients Candidates to PCI (n=130)
Baseline CK-MB mass and/or Tp, serum creatinine, lipids, CRP, AST, ALT and EPC
Placebo
Atorvastatin 
80 + 40 mg
Rosuvastatin 
40 + 40 mg
Rosuvastatin 5 mg +
Ezetimibe 10 mg
N=32 N=34 N=32N=32
12-months MACE (death, myocardial, infarction, the need for additional revascularization)
Lipids, EPC, Angiopgraphic follow-up and OCT after 3 months 
SECOND 
RANDOMIZATION
Atorvastatin Low (20 mg) 
Dose Group (n = 64)
Atorvastatin High (80 mg) 
Dose Group (n = 66)
The REMEDY-EPC late substudy
Fig. 3 Study design of the REMEDY-EPC late sub-study. Diabetic
patients enrolled will be randomized in 4 groups according to the
treatment strategy reported in Fig. 1. Sampling for EPC levels will be
performed before the administration of the tested treatments, at 24 h and
3-month after PCI. At discharge, diabetic patients will be further
randomized in 2 groups: 1) receiving standard background treatment
and high (80 mg) atorvastatin dose for 3 months; and 2) receiving
standard background treatment and low (20 mg) atorvastatin dose for
3 months. Patients will be scheduled for re-hospitalization at 3-month in
order to assess 1) EPC levels, and b) degree of DES re-endothelialization
and neointimal hyperplasia by OCT evaluation
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on the OCT analysis are reported in Appendix 2. Serious
events and any other safety issues will be reviewed by an
independent Data Monitoring and Safety Committee. All
events will be adjudicated by a Clinical Events Committee
(CEC), blinded to treatment assignment. At least 2 members
of the CEC review clinical data and relevant documentation
and determine whether endpoints have occurred according to
the study definitions. In case of disagreement between re-
viewers, a third member of the CEC will adjudicate the event,
and data will be considered by the entire committee if 2 of the
3 reviewers do not agree.
Power Calculations and Statistical Analysis
A total of 1080 patients will be enrolled (270 per arm).
Treatment with atorvastatin in both stable and unstable coro-
nary syndromes has been associated with a 50–90% reduction
of periprocedural MI [6, 8]. Sample size calculation has been
performed to test the hypothesis of a therapeutic relative gain
over placebo =50 % for at least one out of the 3 tested active
treatments. Additional details on statistical analysis for the
REMEDY-EPC late substudy are reported in Appendix 2.
Descriptive statistic of the baseline characteristics will be pre-
sented separately for each treatment arm. Continuous vari-
ables will be reported as mean (± standard deviation), median
(25th–75th percentiles), minimum and maximum. Counts and
percentage will be computed for categorical variables. All
analyses will be intention-to-treat. The population analysis
will include all randomized patients. An on-treatment sensi-
tivity analysis of the primary outcome will be performed, in-
cluding patients with no major deviations from the protocol.
The percent of patients reaching the primary outcome in each
active treatment arm will be compared with the placebo arm,
and/or other treatment arms, with the Fisher exact test.
Difference in proportions and 95 % confidence intervals will
be computed. The hierarchical process for testing hypotheses
reported above will be applied to control for the overall
type I error. A secondary multivariable analysis of the
primary endpoint will be performed to adjust treatment
effect for potential confounders. Adjusted odds ratios and
95 % confidence intervals will be computed through a
logistic model, and adjusted differences in proportions
and 95 % confidence intervals will be computed through
a loglinear model with identity link. Secondary outcomes
on a categorical scale will be analyzed as the primary
outcome (Fisher exact test; difference in proportions and
95 % confidence interval); secondary outcomes on a con-
tinuous scale will be compared with the Student t test or
the Mann Whitney U test. Mean differences and 95 %
confidence intervals will be computed. All statistical analyses
will be performed using the SPSS 20.0 (SPSS Inc., Chicago,
Illinois) and P values <0.05 will be considered significant.
Discussion
The REMEDY study aims at answering the following unre-
solved clinical questions about the periprocedural use of
statins in patients undergoing PCI:
1) Can the results previously shown with atorvastatin
(a lipophilic statin) be reproduced with rosuvastatin
(a hydrophilic statin)? This question will be answered by
the comparison of the rosuvastatin with the placebo arm. In
the Protective Effect of Rosuvastatin and Antiplatelet
Therapy On contrast-induced acute kidney injury andmyo-
cardial damage in patients with Acute Coronary Syndrome
(PRATO-ACS) study [10] early high-dose rosuvastatin
(40mg on admission followed by 20mg/day) did not show
cardioprotective effects when administered in addition to
high-dose clopidogrel in statin-naïve non-ST-elevation
acute coronary syndrome patients scheduled for early
invasive strategy. Accordingly, the ROSEMARY study
[28] suggests that early high-dose rosuvastatin therapy
(40 mg before treatment plus maintenance for 7 days)
in patients with ST elevation MI undergoing primary
PCI did not improve periprocedural myocardial perfu-
sion or reduce infarct volume measured by magnetic
resonance imaging compared with the conventional
low-dose rosuvastatin regimen. On the contrary, in the
ROMA trial, high loading dose of rosuvastatin (40 mg)
within 24 h before elective PCI decreased the incidence
of periprocedural MI compared to the standard treat-
ment [29]. Furthermore, Takano et al. [30] reported that
the incidence of periprocedural MI was reduced more
effectively by high-dose than by low-dose rosuvastatin
in statin-näive patients.
2) Can a dose of rosuvastatin, more potent in terms of LDL
cholesterol reduction and HMG-CoA reductase inhibi-
tion, further improve on the results of the ARMYDA-
ACS study [8]? This question will be answered by the
comparison of the atorvastatin with the rosuvastatin
arm. This issue has been previously addressed in the
ROMA II trial [12] comparing a reloading dose of
rosuvastatin (40 mg) and atorvastatin (80 mg) adminis-
tered within 24 h before PCI in reducing the rate of
periprocedural MI and major cardiac and cerebrovascular
events in stable patients on chronic statin treatment un-
dergoing elective PCI. Periprocedural MI occurred more
frequently in the control group than in the rosuvastatin
group and in the atorvastatin group. However, there was
no difference between the rosuvastatin group and atorva-
statin group in terms of peri-procedural MI and major
adverse cardiac and cerebrovascular events at follow-up.
3) Are the results obtained with statins related to their ability
to impact on LDL-C or to some of the putative
Bpleiotropic^ effects (independent of LDL-C reduction
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and related to the many pathways affected by HMG-CoA
reductase inhibition)? Such a question will be tentatively
answered by the comparison of the rosuvastatin arm with
the rosuvastatin low dose + ezetimibe arm. If the
rosuvastatin/ezetimibe combination will produce a similar
reduction of necrosis marker release versus the rosuvastatin
high-dose arm, it is likely that the effect is not due specifi-
cally to HMG-CoA reductase inhibition and possibly attrib-
utable to LDL-C reduction.We do not expect a large reduc-
tion in LDL-C for the short treatments tested here, and it is
also possible that there will be no significant differences
among treatment tested in terms of LDL-cholesterol reduc-
tion. We do not expect a significant impact on the primary
study outcome of the low-dose rosuvastatin/ezetimibe arm,
but the confirmation of such expectation will be anyhow
worthwhile.
4) In addition to these clinical questions, blood sam-
ples taken during the study will allow to investigate
the effects of the study treatments on CI-AKI and
on and EPC levels (REMEDY-EPC substudies) in
the context of periprocedural myocardial damage.
Randomized clinical trials evaluating high-dose versus
usual-dose statin therapy in patients with stable CAD
have shown that intensive lipid lowering results in addi-
tional reduction of vascular events [31–33]. Despite that,
reluctance still exists on high-dose statin therapy, due to
several reasons, including 1) concern about higher rates of
side-effects; 2) need for closer clinical follow-up; and 3)
cost issues [28]. However, the absolute cardiovascular
risk reduction achieved by high-dose statin therapy is
proportional to the absolute baseline risk [34]. Due to this
uncertainty, different strategies in the usage of high-dose
statins in patients with stable CAD have been adopted
[35]. The expected benefit afforded by such an intensive
statin regimen is a 5 % proportional reduction in the inci-
dence of major cardiovascular events per 10 mg/dl of
LDL-C reduction [35, 36]. The present study will clarify
whether a higher-than-expected clinical benefit can be
explained by the non-lipid-related pleiotropic effects,
such as the increase in circulating EPC levels. Indeed, a
low number of circulating EPCs has been associated with
an increased risk for cardiac death and all other coronary
events [32, 37] reviewed in [38]. Enhancement of EPCs
has been considered one of the most promising therapeu-
tic alternatives for cardiovascular disease [39]. As an ex-
ample, it has been reported that for every 10 CFU increase
in EPCs, a patient’s likelihood for multivessel coronary
disease declined by 20 % [40]. The process of EPC mo-
bilization leads to accelerated re-endothelization. Several
pharmacological pathways may mobilize and increase
EPCs [41, 42], and statin therapy is the most studied so
far [43, 44]. The REMEDY-EPC substudies are the first
randomized studies assessing whether a dose–response
relationship exists between statin therapy and EPC levels.
A result in this direction will support an important addi-
tional mechanism by which intensive statin dose may
improve outcome after PCI. Furthermore, it will offer an
additional marker (beside LCL-C levels) to assess the
benefit of statin therapy after PCI.
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